Skip to main content
SPARC - Logo
Innovations Inspired by life
Menu

Hamburger

  • Our Company
    • Who we are
    • History
    • Culture
    • Board of Directors
    • Leadership Team
  • OUR RESEARCH
    • Therapeutic focus
    • Delivery Technologies
    • Research Programs
    • R&D Pipeline
  • Our Medicines
    • Xelpros®
    • Elepsia® XR
  • Business Development
    • Strategy
    • Partner with us
  • Accreditations And Approvals
    • Good Laboratory Practice
  • Investors
    • Who we are
    • Financials
    • Annual reports
    • Presentations
    • Chairman's Speech
    • Committees of BOD's
    • Shareholding pattern
    • Announcements & Disclosures
    • Policies & Codes
    • Listing Information
    • Board of Directors
    • FAQ’s, Guide Book and Forms for Shareholders
    • Investors Contact
    • Go green
    • IEPF
  • Media
    • Press Releases
    • Presentations
  • Careers
    • Overview
    • Apply Now
  • Contact Us
Our Research » Delivery Technologies
  • Delivery Technologies
    • GRID™
    • Wrap Matrix™
    • Abuse Deterrent Program
    • Nanotecton™ Technology
    • Dry Powder Inhalation
    • TearAct™
    • Lipixelle™
    • Gel Free Reservoir™

Abuse Deterrent Program

  • Prescription opioid abuse epidemic

    Non medical use of prescription opioids in USA has increased over threefold since 1990 to epidemic proportion.1 Approximately 100 million adults in the United States experience pain that can affect performance on daily tasks, quality of life, and productivity in the workplace2.Approximately 4.5 million individuals use prescription pain medications for nonmedical purposes3.

    The rate of opioid overdoses has tripled since 20004. In 2014, rates of opioid overdose deaths increased significantly, from 7.9 per 100,000 in 2013 to 9.0 per 100,000 – a 14% increase5. In the same year, prescription opioids were involved in almost 19,000 deaths6.

  • Routes of opioid abuse

    Opioids can be abused and misused in a variety of ways. For example, an abuser may swallow a greater quantity of the unaltered drug than what is prescribed. This typically occurs with extended-release opioids. Also, abusers may crush extended-release opioids and ingest the drug in a number of ways, including: Swallowing, Snorting, Smoking or Dissolving and injecting7.

  • Abuse Deterrent opioid formulations

    Abuse-deterrent opioids are formulated to deter abuse and misuse of the drug. The goal of abuse-deterrent opioids is to limit access to or attractiveness of the active ingredient that is highly attractive to abusers, while still assuring the safe and effective release of the medication for patients7.

    The FDA guidance provides that abuse-deterrent formulations are categorized into one of the following groups: Physical/Chemical barriers, Agonist/Antagonist combinations, Aversion, Delivery system, new molecular entities and Prodrug, Combination and Novel approaches7.

    SPARC has developed an abuse deterrent technology that has ability to deter the most common route of abuse - oral ingestion of multiple pills. It is designed to deliver clinically effective dose if used as prescribed. Upon ingestion of multiple pills the technology reduces and delays the release of drug, thereby resulting in lower peak plasma concentration. The technology also has ability to tailor the number of pills beyond which release inhibition is desired.

  • Additionally, the technology can also deter drug abuse by snorting or injecting and can prevent the drug extraction by common solvents.

1. Hall AJ, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA, 2008; 300: 2613-20. 2.Institute of Medicine. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education, and research. Washington, DC: The National Academies Press, 3.Substance Abuse and Mental Health Services Administration, Centre for Behavioural Health Statistics and Quality, The NSDUH Report: Substance and Use and Mental Health Estimates from the 2013 National Survey on Drug Use and Health: Overview of Findings, Sept. 4, 2014, 4.Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014, Morbidity and Mortality Weekly Report by US Department of Health and Human Services / Centres for Disease Control and Prevention, December 18, 2015 Vol. 64 Pg. No.: 1-5, 5.Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014, Morbidity and Mortality Weekly Report by US Department of Health and Human Services / Centres for Disease Control and Prevention, January 1, 2016 Vol. 64 Nos. 50 & 51, Pg. No.: 1378-1382), 6.A Proactive Response to Prescription Opioid Abuse by Robert M. Califf et.al, Special Report in The New England Journal of Medicine, February 9, 2016, 7.U.S. Food and Drug Administration, Draft Guidance for Industry: Abuse-Deterrent Opioids-Evaluation and Labeling, April 2015
Image
device-icon
Technology front

Non medical use of prescription opioids in USA has increased over threefold since 1990 to epidemic proportion. Approximately 100 million adults in the United States experience pain that can affect performance on daily tasks, quality of life, and productivity in the workplace.Approximately 4.5 million individuals use prescription pain medications for non-medical purposes.

Our Company

  • Who we are
  • history
  • Culture
  • board of directors
  • Leadership team

Our Research

  • Therapeutic focus
  • Delivery Technologies
  • Research Programs
  • R&D Pipeline

Investor Relations

  • Financials
  • Announcements & Disclosures
  • Shareholding pattern
  • Listing Information

Quick Links

Quick Links

  • Business Development
  • Investors
  • Media
  • Careers

Social Connect

  • twitter
  • linkedin

Employee Portal »

Copyright © 2019. Sun Pharma Advanced Research Company Ltd. All rights reserved.
Terms of Use  |   Archival Policy   |   Sitemap
Site Credits